PF Stock Recent News

MADRID--(BUSINESS WIRE)--“We would like to thank the investigation site team and particularly the investigators and proctors in this groundbreaking first-in human trial and for enabling the publication of these important validating results.” Peter Hinchliffe, CEO MedLumics “Join us as we raise our Series B funding of €15m to reach our regulatory clinical trial readiness milestone. We are ready to move forward with these results toward treating the 100 million Atrial Fibrillation patients global.